{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:18:23Z","timestamp":1788830303927,"version":"build-2803163510"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vph.2014.12.003","type":"journal-article","created":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T05:19:12Z","timestamp":1420780752000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Critical insights into the beneficial and protective actions of the kallikrein\u2013kinin system"],"prefix":"10.1016","volume":"64","author":[{"given":"Domenico","family":"Regoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Fernand","family":"Gobeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2014.12.003_bb0005","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","article-title":"2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC Task Force for the Management of Arterial Hypertension","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2014.12.003_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2014.868629","article-title":"2013 ESH\/ESC Practice Guidelines for the Management of Arterial Hypertension","volume":"23","author":"Mancia","year":"2013","journal-title":"Blood Press"},{"key":"10.1016\/j.vph.2014.12.003_bb0015","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/eurheartj\/ehs108","article-title":"Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?","volume":"33","author":"Ruschitzka","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2014.12.003_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40292-014-0038-3","article-title":"Clinical management of drug-induced hypertension. 2013 practical recommendations of the Italian Society of Hypertension (SIIA)","volume":"21","author":"Virdis","year":"2014","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.vph.2014.12.003_bb0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jamda.2013.02.002","article-title":"Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs","volume":"14","author":"Wehling","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.vph.2014.12.003_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/14779072.3.1.15","article-title":"Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril","volume":"3","author":"Ferrari","year":"2005","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2012.04.002","article-title":"Impact of kinins in the treatment of cardiovascular diseases","volume":"135","author":"Regoli","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0040","first-page":"17","article-title":"New evidence for endothelial protection","volume":"34","author":"Taddei","year":"2012","journal-title":"Medicographia"},{"issue":"Suppl. 2","key":"10.1016\/j.vph.2014.12.003_bb0045","article-title":"Mechanisms involved in the progressive pressor response to very small amounts of angiotensin in conscious rabbits","volume":"21","author":"Dickinson","year":"1967","journal-title":"Circ Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0050","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/01.HYP.14.4.396","article-title":"Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins","volume":"14","author":"Luft","year":"1989","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2014.12.003_bb0055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/01.HYP.36.4.549","article-title":"Development of hypertension induced by subpressor infusion of angiotensin II: role of sensory nerves","volume":"36","author":"Wu","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2014.12.003_bb0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.coph.2011.01.009","article-title":"Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension","volume":"11","author":"Navar","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0065","first-page":"258","article-title":"The role of the renin\u2013angiotensin system In blood pressure regulation and kidney function","volume":"90","author":"Gross","year":"1964","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.vph.2014.12.003_bb0070","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin\u2013angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.vph.2014.12.003_bb0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.intimp.2007.08.022","article-title":"Assembly, activation, and physiologic influence of the plasma kallikrein\/kinin system","volume":"8","author":"Schmaier","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000236474","article-title":"Control of the circulation by endothelial mediators. Inaugural G.B. West Memorial Lecture","volume":"101","author":"Vane","year":"1993","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.vph.2014.12.003_bb0085","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcp.21933","article-title":"Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli","volume":"222","author":"Bovenzi","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0090","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1152\/ajpendo.00382.2005","article-title":"Role of bradykinin B1 and B2 receptors in normal blood pressure regulation","volume":"291","author":"Duka","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.vph.2014.12.003_bb0095","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.peptides.2011.06.010","article-title":"Role of vascular Kinin B1 and B2 receptors in endothelial nitric oxide metabolism","volume":"32","author":"Loiola","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.vph.2014.12.003_bb0100","doi-asserted-by":"crossref","first-page":"H1602","DOI":"10.1152\/ajpheart.00982.2010","article-title":"Role of M1, M3, and M5 muscarinic acetylcholine receptors in cholinergic dilation of small arteries studied with gene-targeted mice","volume":"300","author":"Gericke","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0031-6997(24)01328-0","article-title":"International Union of Pharmacology. XIII. Classification of histamine receptors","volume":"49","author":"Hill","year":"1997","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.vph.2014.12.003_bb0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/pr.58.1.5","article-title":"Pathophysiology and therapeutic potential of purinergic signaling","volume":"58","author":"Burnstock","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.vph.2014.12.003_bb0115","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1172\/JCI0215490","article-title":"The plasma kallikrein\u2013kinin system counterbalances the renin\u2013angiotensin system","volume":"109","author":"Schmaier","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2014.12.003_bb0120","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0167-4889(02)00393-2","article-title":"Tissue kallikrein is synthesized and secreted by human vascular endothelial cells","volume":"1593","author":"Yayama","year":"2003","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2014.12.003_bb0125","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.thromres.2014.03.018","article-title":"Physiologic activities of the contact activation system","volume":"133","author":"Schmaier","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0165-6147(90)90179-C","article-title":"G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides","volume":"11","author":"Mousli","year":"1990","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.vph.2014.12.003_bb0135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2005.05.038","article-title":"Clots, kinins and coronaries","volume":"183","author":"Cruden","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2014.12.003_bb0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0735-1097(02)80994-9","article-title":"ACE inhibitors improve endothelial function of coronary arterioles from patients with atherosclerosis by influencing local kinin release","volume":"39","author":"Tiefenbacher","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00380-011-0124-6","article-title":"Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb","volume":"27","author":"Cruden","year":"2012","journal-title":"Heart Vessels"},{"key":"10.1016\/j.vph.2014.12.003_bb0150","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1016\/S1520-765X(03)90062-9","article-title":"Contribution of bradykinin to the cardioprotective effects of ACE inhibitors","volume":"5","author":"Murphey","year":"2003","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.vph.2014.12.003_bb0155","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","article-title":"Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans","volume":"95","author":"Hornig","year":"1997","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2014.12.003_bb0160","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00005344-200109011-00004","article-title":"Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events","volume":"37","author":"Enseleit","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0165","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1517\/14656566.2010.521742","article-title":"Which antihypertensive drugs are the most nephroprotective and why?","volume":"11","author":"Cravedi","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.vph.2014.12.003_bb0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrcardio.2014.131","article-title":"Decade in review-hypertension: the past decade in hypertension-facts, hopes, and hypes","volume":"11","author":"Unger","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0175","doi-asserted-by":"crossref","first-page":"30H","DOI":"10.1016\/S0002-9149(03)00432-6","article-title":"Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease","volume":"91","author":"McFarlane","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/01.RES.34.6.824","article-title":"Hydrolysis of bradykinin by angiotensin-converting enzyme","volume":"34","author":"Dorer","year":"1974","journal-title":"Circ Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0185","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1016\/S0021-9258(18)98378-X","article-title":"Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides","volume":"268","author":"Jaspard","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.12.003_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2007.07.061","article-title":"Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE","volume":"577","author":"Ceconi","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0195","doi-asserted-by":"crossref","first-page":"10190","DOI":"10.1073\/pnas.1005144107","article-title":"Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice","volume":"107","author":"Kakoki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2014.12.003_bb0200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MNH.0b013e32834d54b1","article-title":"The kallikrein\u2013kinin system and oxidative stress","volume":"21","author":"Kayashima","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.vph.2014.12.003_bb0205","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ki.2011.499","article-title":"The kallikrein\u2013kinin system in diabetic nephropathy","volume":"81","author":"Tomita","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.vph.2014.12.003_bb0210","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2174\/138161211797416002","article-title":"Kinins as therapeutic agents in cardiovascular and renal diseases","volume":"17","author":"Alhenc-Gelas","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.vph.2014.12.003_bb0215","doi-asserted-by":"crossref","first-page":"R897","DOI":"10.1152\/ajpregu.2000.278.4.R897","article-title":"Kinins in humans","volume":"278","author":"Duncan","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(25)06820-6","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors","volume":"47","author":"Linz","year":"1995","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.vph.2014.12.003_bb0225","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1042\/cs0870567","article-title":"Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects","volume":"87","author":"Pellacani","year":"1994","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.vph.2014.12.003_bb0230","doi-asserted-by":"crossref","first-page":"G13","DOI":"10.1093\/eurheartj\/sun025","article-title":"Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection","volume":"10","author":"Ferrari","year":"2008","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.vph.2014.12.003_bb0235","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1570161112666140226121627","article-title":"Kinin receptors in vascular biology and pathology","volume":"12","author":"Couture","year":"2014","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0240","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ki.2008.647","article-title":"The kallikrein\u2013kinin system in health and in diseases of the kidney","volume":"75","author":"Kakoki","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.vph.2014.12.003_bb0245","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/CIRCRESAHA.108.179952","article-title":"Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential","volume":"103","author":"Krankel","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0250","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.CIR.99.3.434","article-title":"Amelioration by quinapril of myocardial infarction induced by coronary occlusion\/reperfusion in a rabbit model of atherosclerosis: possible mechanisms","volume":"99","author":"Hoshida","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.12.003_bb0255","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14728222.2013.827664","article-title":"Targeting the \u2018Janus face\u2019 of the B2-bradykinin receptor","volume":"17","author":"Blaes","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.vph.2014.12.003_bb0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1113\/expphysiol.2004.028464","article-title":"Kallikrein\u2013kinin in stroke, cardiovascular and renal disease","volume":"90","author":"Chao","year":"2005","journal-title":"Exp Physiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0265","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/01.HYP.23.4.439","article-title":"Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides","volume":"23","author":"Campbell","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2014.12.003_bb0270","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/jpet.106.104026","article-title":"Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans","volume":"318","author":"Murphey","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0275","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/hsz-2012-0295","article-title":"Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist","volume":"394","author":"Savard","year":"2013","journal-title":"Biol Chem"},{"key":"10.1016\/j.vph.2014.12.003_bb0280","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2012.249","article-title":"Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial","volume":"93","author":"Balaguer","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0285","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/ATVBAHA.112.300395","article-title":"Endogenous tissue plasminogen activator enhances fibrinolysis and limits thrombus formation in a clinical model of thrombosis","volume":"33","author":"Lucking","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.12.003_bb0290","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V66.4.835.835","article-title":"Tissue plasminogen activator release in vivo in response to vasoactive agents","volume":"66","author":"Smith","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.vph.2014.12.003_bb0295","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1016\/j.bmc.2011.10.045","article-title":"Conformationally restricted analogs of the direct thrombin inhibitor FM 19","volume":"19","author":"Girnys","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.vph.2014.12.003_bb0300","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1538-7836.2008.02937.x","article-title":"Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo","volume":"6","author":"Nieman","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2014.12.003_bb0305","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0008-6363(01)00514-4","article-title":"Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury","volume":"53","author":"Prieto","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0310","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coph.2006.09.007","article-title":"Effects of anti-hypertensive drugs on vessel rarefaction","volume":"7","author":"Battegay","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0315","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1172\/JCI26958","article-title":"Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors","volume":"116","author":"Kakoki","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2014.12.003_bb0320","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/01.CIR.0000046268.59922.A4","article-title":"Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin","volume":"107","author":"Pretorius","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.12.003_bb0325","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10557-007-6068-5","article-title":"Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies","volume":"21","author":"Ceconi","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10557-010-6244-x","article-title":"Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium","volume":"24","author":"Ferrari","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0335","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/HYPERTENSIONAHA.108.123729","article-title":"Bradykinin protects against oxidative stress-induced endothelial cell senescence","volume":"53","author":"Oeseburg","year":"2009","journal-title":"Hypertension"},{"issue":"Suppl. 5","key":"10.1016\/j.vph.2014.12.003_bb0340","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003495-199700545-00009","article-title":"Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?","volume":"54","author":"Remme","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2014.12.003_bb0345","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCULATIONAHA.112.118117","article-title":"Novel insights into the critical role of bradykinin and the kinin B2 receptor for vascular recruitment of circulating endothelial repair-promoting mononuclear cell subsets: alterations in patients with coronary disease","volume":"127","author":"Krankel","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.12.003_bb0350","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1586\/14779072.7.3.215","article-title":"Helping the circulatory system heal itself: manipulating kinin signaling to promote neovascularization","volume":"7","author":"Krankel","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0355","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/01.HYP.0000070956.57418.22","article-title":"Different effect of antihypertensive drugs on conduit artery endothelial function","volume":"41","author":"Ghiadoni","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2014.12.003_bb0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","article-title":"ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT","volume":"73","author":"Ceconi","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0365","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/HJH.0b013e3280115901","article-title":"Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients","volume":"25","author":"Ghiadoni","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2014.12.003_bb0370","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/HYPERTENSIONAHA.114.04221","article-title":"Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the hoorn study","volume":"64","author":"van Sloten","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2014.12.003_bb0375","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1463-1326.2011.01521.x","article-title":"Blockade of kinin B(1) receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance","volume":"14","author":"Dias","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.vph.2014.12.003_bb0380","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.hjh.0000160215.78973.ba","article-title":"Effects of glucose and insulin on the development of oxidative stress and hypertension in animal models of type 1 and type 2 diabetes","volume":"23","author":"El Midaoui","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.vph.2014.12.003_bb0385","doi-asserted-by":"crossref","first-page":"e12622","DOI":"10.1371\/journal.pone.0012622","article-title":"Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications","volume":"5","author":"Dias","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2014.12.003_bb0390","first-page":"111","article-title":"The kallikrein\u2013kinin system in diabetic retinopathy","volume":"69","author":"Bhat","year":"2014","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0395","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.2337\/db10-1260","article-title":"Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats","volume":"60","author":"Clermont","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.vph.2014.12.003_bb0400","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1160\/TH13-02-0179","article-title":"Role of plasma kallikrein in diabetes and metabolism","volume":"110","author":"Feener","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2014.12.003_bb0405","first-page":"507","article-title":"Targeting the kallikrein\u2013kinin system as a new therapeutic approach to diabetic retinopathy","volume":"11","author":"Pruneau","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.vph.2014.12.003_bb0410","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0895-7061(96)00319-6","article-title":"Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy","volume":"10","author":"Villa","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.vph.2014.12.003_bb0415","doi-asserted-by":"crossref","first-page":"511","DOI":"10.33549\/physiolres.932496","article-title":"Antioxidant\/oxidant status and cardiac function in bradykinin B(1)- and B(2)-receptor null mice","volume":"62","author":"Delemasure","year":"2013","journal-title":"Physiol Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0420","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1476-5381.1991.tb12248.x","article-title":"Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies","volume":"102","author":"Hock","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0425","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1476-5381.1991.tb12249.x","article-title":"Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies","volume":"102","author":"Wirth","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0430","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1111\/trf.12674","article-title":"Treatment of hereditary angioedema: a review","volume":"54","author":"Bhardwaj","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.vph.2014.12.003_bb0435","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2014.12.003_bb0440","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.12.003_bb0445","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/01.HYP.23.6.813","article-title":"Corcoran lecture. Angiotensin-converting enzyme inhibition and the heart","volume":"23","author":"Gavras","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2014.12.003_bb0450","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1089\/hum.2011.123","article-title":"Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity","volume":"23","author":"Yao","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0455","series-title":"The kallikrein\u2013kinin system in health and disease","first-page":"63","article-title":"Kinin paracrine hormone","author":"Carretero","year":"1989"},{"key":"10.1016\/j.vph.2014.12.003_bb0460","first-page":"37","article-title":"Tissue kallikrein\u2013kinin therapy in hypertension and organ damage","volume":"69","author":"Chao","year":"2014","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0465","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1515\/bc.2010.042","article-title":"Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing","volume":"391","author":"Chao","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.vph.2014.12.003_bb0470","first-page":"145","article-title":"Genetic manipulation and genetic variation of the kallikrein\u2013kinin system: impact on cardiovascular and renal diseases","volume":"69","author":"Girolami","year":"2014","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.vph.2014.12.003_bb0475","doi-asserted-by":"crossref","first-page":"e103981","DOI":"10.1371\/journal.pone.0103981","article-title":"Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus","volume":"9","author":"Kolodka","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2014.12.003_bb0480","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.113.203927","article-title":"Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes","volume":"346","author":"Potier","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0485","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2174\/138161206778194051","article-title":"Kinins and cardiovascular diseases","volume":"12","author":"Su","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.vph.2014.12.003_bb0490","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cei.12413","article-title":"Modulation of kallikrein\u2013kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis","volume":"178","author":"Uzawa","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vph.2014.12.003_bb0495","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.114.219196","article-title":"Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice","author":"Desposito","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0500","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-12-0937","article-title":"Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man","volume":"110","author":"Waeckel","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2014.12.003_bb0505","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2014.12.003_bb0510","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cjca.2014.02.002","article-title":"The 2014 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"30","author":"Dasgupta","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0515","first-page":"634","article-title":"ACEIs for cardiovascular risk reduction\u2014have we taken our eye off the ball?","volume":"42","author":"Sindone","year":"2013","journal-title":"Aust Fam Physician"},{"key":"10.1016\/j.vph.2014.12.003_bb0520","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin\u2013angiotensin\u2013aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2014.12.003_bb0525","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"Suppl. 6","key":"10.1016\/j.vph.2014.12.003_bb0530","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/00005344-199015061-00005","article-title":"Some old and some new ideas on kinin metabolism","volume":"15","author":"Erd\u00f6s","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.vph.2014.12.003_bb0535","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/2251142b0","article-title":"Some properties of angiotensin converting enzyme in the lung in vivo","volume":"225","author":"Ng","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.vph.2014.12.003_bb0540","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/HYPERTENSIONAHA.110.155051","article-title":"Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells","volume":"56","author":"Zhu","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2014.12.003_bb0545","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.12.003_bb0550","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1124\/jpet.106.117259","article-title":"Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade","volume":"320","author":"LeFebvre","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0555","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/01.HYP.36.1.132","article-title":"Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men","volume":"36","author":"Squire","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2014.12.003_bb0560","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2008.01.003","article-title":"Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure","volume":"19","author":"Carey","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.vph.2014.12.003_bb0565","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5414\/CP201514","article-title":"Adverse drug reactions (ADRs) associated with hospital admissions\u2014elderly female patients are at highest risk","volume":"49","author":"Hofer-Dueckelmann","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0570","article-title":"Angiotensin converting enzyme inhibitor induced angioedema","author":"Bezalel","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.vph.2014.12.003_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2014.07.108","article-title":"The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease","author":"Brugts","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0580","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin\u2013angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0585","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1016\/0002-9343(92)90153-3","article-title":"Perindopril versus captopril: efficacy and acceptability in an Italian multicenter trial","volume":"92","author":"Agabiti-Rosei","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.vph.2014.12.003_bb0590","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/00045391-199510000-00013","article-title":"A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough","volume":"2","author":"David","year":"1995","journal-title":"Am J Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0595","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vph.2014.12.003_bb0600","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jclinepi.2006.06.017","article-title":"Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is","volume":"60","author":"Tumanan-Mendoza","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0605","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrcardio.2012.33","article-title":"Key advances in antihypertensive treatment","volume":"9","author":"Paulis","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.vph.2014.12.003_bb0610","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.2174\/1381612811319170005","article-title":"Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers","volume":"19","author":"Imaizumi","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.vph.2014.12.003_bb0615","doi-asserted-by":"crossref","first-page":"61","DOI":"10.12703\/P6-61","article-title":"Interfering with mineralocorticoid receptor activation: the past, present, and future","volume":"6","author":"Dorrance","year":"2014","journal-title":"F1000Prime Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2014.12.003_bb0620","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ndt\/gft402","article-title":"Aldosterone synthase inhibitors in cardiovascular and renal diseases","volume":"29","author":"Namsolleck","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.vph.2014.12.003_bb0625","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2014.12.003_bb0630","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2014.04.007","article-title":"Biased ligands at G-protein-coupled receptors: promise and progress","volume":"35","author":"Violin","year":"2014","journal-title":"Trends Pharmacol Sci"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T15:44:51Z","timestamp":1747410291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":126,"alternative-id":["S1537189115000026"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2014.12.003","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical insights into the beneficial and protective actions of the kallikrein\u2013kinin system","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}